Summary
Losartan Potassium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. ClinicalTrials.gov lists 8 registered trials linking Losartan Potassium to Hypertension: 7 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00994617). It plans or enrolled 600 participants. Registration activity spans 1999 to 2021. The literature layer holds 6 publications for this pair: 1 meta-analysis and 5 clinical trial publications. Publication years run from 1995 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 64.0 (trials 30.0, literature 14.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 7 completed, 1 other |
| Linked publications | 6 (5 clinical trial publications, 1 meta-analysis) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06718062 | Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia 2021 | completed | Phase 4 | 66 |
| NCT00157963 | Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) 2005 | completed | Phase 4 | 174 |
| NCT03276598 | A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension 1999 | completed | Phase 4 | 233 |
| NCT00994617 | Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension 2010 | status unknown | Phase 4 | 600 |
| NCT05199129 | Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients 2021 | completed | Phase 3 | 166 |
| NCT00219141 | Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension 2005 | completed | Phase 3 | 460 |
| NCT00354991 | Hyzaar Asia HEAALTH (0954A-950) 2006 | completed | Phase 3 | 437 |
| NCT01307046 | MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) 2011 | completed | Phase 3 | 336 |
Published literature
- Clinical trial publication Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate HypertensionSung KC, Park K, Kim DH et al. · Journal of the American College of Cardiology · 2026 · PMID 41670573
- Clinical trial publication Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertensionSung KC, Hong SJ, Rhee MY et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2023 · PMID 37095689
- Clinical trial publication Effect of Songlingxuemaikang on mild essential hypertension in patients: a randomized parallel-controlled studyZhu GH, Sun XP, Ding CT et al. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2021 · PMID 34708639
- Clinical trial publication A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and HyperlipidemiaLee HY, Kim SY, Choi KJ et al. · Clinical therapeutics · 2017 · PMID 29150250
- Clinical trial publication Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III StudyHong SJ, Jeong HS, Han SH et al. · Clinical therapeutics · 2017 · PMID 28939406
- Meta-analysis Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitorsGoldberg AI, Dunlay MC, Sweet CS · Journal of hypertension. Supplement : official journal of the International Society of Hypertension · 1995 · PMID 18800461
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Losartan Potassium approved for Hypertension?
Losartan Potassium has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Losartan Potassium in clinical trials for Hypertension?
ClinicalTrials.gov lists 8 registered trials linking Losartan Potassium to Hypertension: 7 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00994617). It plans or enrolled 600 participants. Registration activity spans 1999 to 2021.
What does the evidence show for Losartan Potassium in Hypertension?
Losartan Potassium has both completed registered trials and synthesis-level publications linked to Hypertension. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.